Germany Gene Therapy Market Size & Outlook, 2023-2030
- Biotechnology
- Gene Expression & Gene Therapy
- Gene Therapy Market Outlook
- Gene Expression & Gene Therapy
Germany Gene Therapy Market, 2018-2030 (US$M)
Global Market
Related Markets
Ask a question about the gene therapy market
Germany gene therapy market highlights
- The Germany gene therapy market generated a revenue of USD 373.8 million in 2023 and is expected to reach USD 1,453.7 million by 2030.
- The Germany market is expected to grow at a CAGR of 21.4% from 2024 to 2030.
- In terms of segment, aav was the largest revenue generating vector type in 2023.
- AAV is the most lucrative vector type segment registering the fastest growth during the forecast period.
Gene therapy market data book summary
| Market revenue in 2023 | USD 373.8 million |
| Market revenue in 2030 | USD 1,453.7 million |
| Growth rate | 21.4% (CAGR from 2024 to 2030) |
| Largest segment | Aav |
| Fastest growing segment | AAV |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Lentivirus, AAV, RetroVirus & gamma RetroVirus, Modified Herpes Simplex Virus, Other Vector Type |
| Key market players worldwide | Regenxbio Inc, Oxford Biomedical Research, Bristol-Myers Squibb Co, Sanofi SA, Ultragenyx Pharmaceutical Inc, Roche Holding AG ADR, Bluebird bio Inc, Novartis AG ADR, UniQure NV, Cellectis SA, Sangamo Therapeutics Inc, Benitec Biopharma Inc, SiBiono GeneTech, Transgene SA, Gensight Biologics SA, Astellas Pharma Inc |
Other key industry trends
- In terms of revenue, Germany accounted for 4.4% of the global gene therapy market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, UK gene therapy market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 2,470.1 million by 2030.
In January 2020, a U.S.-based company—bluebird bio—launched its first gene therapy for transfusiondependent beta-thalassemia (blood disorder) in Germany. apceth Biopharma— a German manufacturer—is working with bluebird for the production of Zynteglo, the gene therapy launched by bluebird.
In addition, major global companies in the gene therapy market, such as Takeda Pharmaceuticals and Bayer AG, are engaged in undertaking various strategic initiatives to develop new gene therapy products in the country, thereby leading to increasing demand for gene therapy.
For instance, in August 2019, Bayer AG entered into the gene therapies segment by acquiring a U.S. biotech company—BlueRock Therapeutics. The presence of such companies is anticipated to contribute to the revenue of the country.
Key Regions:U.S., UK, Japan, South Korea, China
No credit card required*
Publish Date: Mar 17, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Gene Therapy Market Scope
Gene Therapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Novartis AG ADR | View profile | 76,057 | Lichtstrasse 35, Basel, Switzerland, 4056 | www.novartis.com |
| Roche Holding AG ADR | View profile | 103,605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | www.roche.com |
| Sanofi SA | View profile | 87,994 | 46, avenue de la Grande Armée, Paris, France, 75017 | www.sanofi.com |
| Bristol-Myers Squibb Co | View profile | 34,100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | www.bms.com |
| UniQure NV | View profile | 480 | Paasheuvelweg 25, Amsterdam, NH, Netherlands, 1105 BP | www.uniqure.com |
| SiBiono GeneTech | View profile | 1001-5000 | Shenzhen, Guangdong, China, Asia | www.sibiono.com |
| Cellectis SA | View profile | 216 | 8, rue de la Croix Jarry, Paris, France, 75013 | www.cellectis.com |
| Astellas Pharma Inc | View profile | 14,484 | 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan, 103-8411 | www.astellas.com |
| Bluebird bio Inc | View profile | 323 | 455 Grand Union Boulevard, Somerville, MA, United States, 02145 | www.bluebirdbio.com |
| Sangamo Therapeutics Inc | View profile | 405 | 501 Canal Boulevard, Richmond, CA, United States, 94804 | www.sangamo.com |
Germany Gene Therapy Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Gene Therapy Market Outlook will help companies and investors design strategic landscapes.
Aav was the largest segment with a revenue share of 38.82% in 2023.
Horizon Databook has segmented the Germany gene therapy market based on lentivirus, aav, retrovirus & gamma retrovirus, modified herpes simplex virus, other vector type covering the revenue growth of each sub-segment from 2018 to 2030.
In January 2020, a U.S.-based company—bluebird bio—launched its first gene therapy for transfusiondependent beta-thalassemia (blood disorder) in Germany. apceth Biopharma— a German manufacturer—is working with bluebird for the production of Zynteglo, the gene therapy launched by bluebird.
In addition, major global companies in the gene therapy market, such as Takeda Pharmaceuticals and Bayer AG, are engaged in undertaking various strategic initiatives to develop new gene therapy products in the country, thereby leading to increasing demand for gene therapy.
For instance, in August 2019, Bayer AG entered into the gene therapies segment by acquiring a U.S. biotech company—BlueRock Therapeutics. The presence of such companies is anticipated to contribute to the revenue of the country.
- Germany Gene Therapy Market Vector Type Outlook (Revenue, USD Million , 2018-2030)
- Lentivirus
- AAV
- RetroVirus & gamma RetroVirus
- Modified Herpes Simplex Virus
- Adenovirus
- Non-viral Plasmid Vector
- Other Vector Type
- Germany Gene Therapy Market Indication Outlook (Revenue, USD Million , 2018-2030)
- Acute Lymphoblastic Leukemia (ALL)
- Inherited Retinal Disease
- Large B-cell Lymphoma
- ADA-SCID
- Melanoma (lesions)
- Beta-Thalassemia Major/SCD
- Head & Neck Squamous Cell Carcinoma
- Peripheral arterial disease
- Spinal Muscular Atrophy (SMA)
- Others
Reasons to subscribe to Gene Therapy Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Gene Therapy Market Outlook databook
- Our clientele includes a mix of Gene Therapy Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany Gene Therapy Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Germany Gene Therapy Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Germany Gene Therapy Market, 2018-2030 (US$M)
Germany gene therapy market statistics, by vector type, 2018-2030 (US$M)
